Work

Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.2025

Authors: Juanita Suzanne Lopez, Rebecca Sophie Kristeleit, Robert Rulach, Noor Md Haris, Mariana Scaranti, Paul James Mulholland, Donna Crawford, Saira Bashir, Caterina Aversa, Alison L. Hannah, Stephanie Anderson, Marc Engelhardt, Thomas Kaindl, Patrice Larger, Phil McKernan, TR Jeffry Evans, Elizabeth Plummer

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, University College Hospital, Beatson West of Scotland Cancer Centre, Freeman Hospital, Royal Marsden Hospital, Basilea Pharmaceutica (Switzerland)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947595033

Cites:

Cited by: 2

Related to: 10